Abstracts tagged "Administrative Data"

Abstract Number: 0183 • ACR Convergence 2023
Barriers and Facilitators to Recruiting Underrepresented Participants for Clinical Trials: Insights from the Lupus Clinical Investigators Network (LuCIN)
Tessa Englund¹, Christine Lee², Julie Hsieh², Richardae Araojo², Julia Mariano¹, Emily McCormick³, Stacie Bell⁴, Albert Roy⁵ and Saira Sheikh¹, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²U.S. Food and Drug Administration, Silver Spring, MD, ³Thurston Arthritis Research Center, Chapel Hill, NC, ⁴Lupus Therapeutics, Lakewood, CO, ⁵Lupus Research Alliance, New York, NY
Background/Purpose: Despite greater prevalence of lupus among diverse, racial and ethnic minority populations, marked gaps exist between populations affected by lupus and those enrolled in…
Abstract Number: 1027 • ACR Convergence 2023
Single-Payer Health Insurance May Not Mitigate Income-Based Differences in Total Hip Arthroplasty Utilization: A Transnational Analysis
Bella Mehta¹, Kaylee Ho², J. Alex Gibbons³, Vicki Ling⁴, Susan Goodman⁵, Michael Parks⁵, Bheeshma Ravi⁶, Fei Wang², Said Ibrahim⁷ and Peter cram⁸, ¹Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ²Weill Cornell Medicine, New York, NY, ³Columbia University Vagelos College of Physicians & Surgeons, New York, NY, ⁴Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, ⁵Hospital for Special Surgery, New York, NY, ⁶Sunnybrook Health Sciences Centre, Toronto, ON, Canada, ⁷Northwell Health, New York, NY, ⁸The University of Texas Medical Branch, Galveston, TX
Background/Purpose: Access to care varies across health systems. Countries with universal health insurance are thought to have less wealth-based health disparities, but it is unclear…
Abstract Number: 1818 • ACR Convergence 2023
Compliance with Romosozumab and Fracture Risk Among Postmenopausal Women in the U.S
Ye Liu¹, Tarun Arora², Jeffrey Curtis¹ and Jingyi Zhang¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Foundation for Advancing Science, Technology, Education, and Research, Birmingham, AL
Background/Purpose: Romosozumab (romo) is a newly approved osteoporosis (OP) medicine for women with postmenopausal OP at high risk of fracture. The utilization pattern of romo…
Abstract Number: 0353 • ACR Convergence 2023
Validation of Claims-based Algorithms for Newly Diagnosed Juvenile Idiopathic Arthritis Using Machine Learning Methods
Patricia Hoffman¹, Lauren Parlett², Daniel Beachler², Daniel Reiff³, Sarah McGuire¹, Sonia Pothraj¹, Lakshmi Moorthy¹, Cynthia Salvant⁴, Dawn Koffman⁵, Sanika Rege⁵, Cecilia Huang⁵, Matthew Iozzio⁵, Kevin Schott², Kevin Haynes⁶, Amy Davidow⁷, Stephen Crystal⁸, Tobias Gerhard⁵, Brian Strom⁹, Carlos Rose¹⁰ and Daniel Horton⁴, ¹Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ²Carelon, Wilmington, DE, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Department of Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ⁵Rutgers Center for Pharmacoepidemiology and Treatment Science, New Brunswick, NJ, ⁶Janssen Pharmaceuticals, Raritan, NJ, ⁷New York University, New York, NY, ⁸Rutgers University, New Brunswick, NJ, ⁹Rutgers, State University of New Jersey, New Brunswick, NJ, ¹⁰Thomas Jefferson University, Philadelphia, PA
Background/Purpose: Administrative claims databases represent important settings for studying large populations with juvenile idiopathic arthritis (JIA), but prior efforts to validate diagnostic algorithms for JIA…
Abstract Number: 1030 • ACR Convergence 2023
Patterns in the Prescription, the Denials of Coverage, and the Delays in Dispensation of Janus Kinase Inhibitors
Thomas Riley¹, Igor Dombrovsky², Michael George³ and Joshua Baker³, ¹Hopsital of the University of Pennsylvania, Springfield, PA, ²Pennsylvania Hospital, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, PA
Background/Purpose: Janus kinase inhibitors (JAKi) have therapeutic benefits in autoimmune conditions. Access to these medications is controlled by insurance carriers through requirements for prior authorizations…
Abstract Number: 1856 • ACR Convergence 2023
Improving Recombinant Zoster Vaccination Rates in Patients Receiving Immunosuppressive Therapy in the Rheumatology Clinic at the Orlando VA Healthcare System – a Quality Improvement Project
Kathlyn Camargo Macias¹, Ravi Shahu Khal¹, Ariail Schmitz², Kathleen McCabe¹, Taylor Kann¹, Marilyn Mosquera³ and Ashwini Komarla⁴, ¹University of Central Florida, Orlando, FL, ²University of Central Florida, St. Cloud, FL, ³University of Central Florida, Casselberry, FL, ⁴ORLANDO VAMC, Orlando, FL
Background/Purpose: Herpes zoster is a painful rash that involves one to three adjacent dermatomes, secondary to reactivation of latent varicella-zoster virus (VZV). About 95 %…
Abstract Number: 0433 • ACR Convergence 2023
DMARD Initiation in Older Adults with New Diagnosis of Late-Onset Rheumatoid Arthritis
Jiha Lee¹, Jonathan Martindale¹, Una Makris², Namrata Singh³, Raymond Yung⁴ and Julie Bynum¹, ¹University of Michigan, Ann Arbor, MI, ²UT Southwestern Medical Center and Dallas VA, Dallas, TX, ³University of Washington, Bellevue, WA, ⁴Michigan Medicine, Ann Arbor, MI
Background/Purpose: The number of older adults living with rheumatoid arthritis (RA) is growing as the world population is aging. Up to one-third of the older…
Abstract Number: 1057 • ACR Convergence 2023
Melanoma and Combination Immune Checkpoint Inhibitors Are More Clearly Associated with the Development of Chronic Inflammatory Arthritis Than Pre-existing Autoimmune Disease: A Cross-Sectional Study of Administrative Health Data
Alexandra Ladouceur¹, Marie Hudson², Hassan Behlouli³, Jeffrey Curtis⁴, Louise Pilote³ and Sasha Bernatsky³, ¹Department of Rheumatology of McGill University and CHU-Bordeaux, Montréal, QC, Canada, ²McGill University, Montréal, QC, Canada, ³Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Immune checkpoint inhibitors (ICIs) improve survival in many malignancies1, by augmenting the immune system's anti-tumor response. However, ICI can result in immune-related adverse events…
Abstract Number: 2008 • ACR Convergence 2023
Comparative Effectiveness of Denosumab versus Alendronate Among Postmenopausal Women with Osteoporosis in the U.S. Medicare Program
Jeffrey Curtis¹, Tarun Arora², Ye Liu¹, Tzu-Chieh Lin³, Leslie Spangler³, Vanessa C. Brunetti³, Robert K. Stad³, Michele McDermott³, Brian D. Bradbury³ and Min Kim³, ¹University of Alabama at Birmingham, Birmingham, AL, ²Foundation for Advancing Science, Technology, Education, and Research, Birmingham, AL, ³Amgen, Inc., Thousand Oaks, CA
Background/Purpose: Although clinical trials have shown that denosumab (Dmab) significantly increases bone mineral density at key skeletal sites more than oral bisphosphonates, evidence is lacking…
Abstract Number: 0457 • ACR Convergence 2023
Biologic Disease Modifying Antirheumatic Drug Use in Immune Checkpoint Inhibitor-Treated Cancer Patients with Rheumatoid Arthritis: Utilization and Overall Survival
Deanna Jannat-Khah¹, Jeffrey R Curtis², Fenglong Xie³, Ashish Saxena⁴ and Anne Bass⁵, ¹Hospital For Special Surgery, New York, NY, ²Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Weill Cornell Medicine, New York, NY, ⁵Hospital for Special Surgery, Weill Cornell Medicine, New York, NY

Background/Purpose: There is a dearth of knowledge around the safety of biologic disease modifying antirheumatic drugs (bDMARDS) in immune checkpoint inhibitor (ICI)-treated rheumatoid arthritis (RA)…
Abstract Number: 1059 • ACR Convergence 2023
Identification of Patients with Immune Checkpoint Inhibitor-Associated Inflammatory Arthritis Using Medicare Claims Data
Anne Bass¹, Fenglong Xie², Alexa Meara³, Deanna Jannat-Khah⁴ and Jeffrey Curtis², ¹Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ²University of Alabama at Birmingham, Birmingham, AL, ³The Ohio State University Wexner Medical Center, Columbus, OH, ⁴Hospital For Special Surgery, New York, NY
Background/Purpose: Immune checkpoint inhibitor (ICI) associated inflammatory arthritis (ICI-IA) has been suggested to occur in approximately 3-6% of ICI-treated patients with cancer1 but most studies…
Abstract Number: 2137 • ACR Convergence 2023
Line of Therapy of Biologics and JAK Inhibitors in RA, PsA and AxSpA: Implications for Design and Uptake of New Drugs and Diagnostics
Jeffrey Curtis¹, Fenglong Xie¹, Yuji Su², Patrick Stewart³ and Amy S. Mudano¹, ¹Illumination Health, Hoover, AL, ²University of Alabama at Birmingham and Illumination Health, Birmingham, AL, ³Illumination Health, Birmingham, AL
Background/Purpose: Patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (AxSpA) have an increasing array of treatment options available, and new blood-based diagnostic…
Abstract Number: 0668 • ACR Convergence 2023
Increased Risk of Cancer in Patients with Systemic Sclerosis: A Population-based Study
Jiwon Hwang¹, Yeonghee Eun², Kyungdo Han³ and Joong Kyong Ahn², ¹Division of Rheumatology, Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon-si, South Korea, ²Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, ³Department of Statistics and Actuarial Science, Soongsil University, Seoul, South Korea
Background/Purpose: Previous studies have shown an association between systemic sclerosis and cancer. However, because the disease is rare, large-scale studies are lacking, especially in Asians.…
Abstract Number: 1102 • ACR Convergence 2023
Finding Lost-to-Care Gout Patients in a Large Community Rheumatology Network: Patient Re-engagement Initiative with Metrics (PRIME)
Amy S. Mudano¹, Jessica Ryan¹, Emily Holladay², Kathleen Methric³, Danielle Grauer⁴, Brian LaMoreaux³, Fenglong Xie¹ and Jeffrey R Curtis⁵, ¹Illumination Health, Hoover, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Horizon Therapeutics, Deerfield, IL, ⁴Illumination Health, Boca Raton, FL, ⁵Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL
Background/Purpose: Treatment of patients with gout can be complex and, given the episodic nature of gout attacks, gout patients may not always return for regular…
Abstract Number: 2240 • ACR Convergence 2023
Persistence to Therapy Among Patients with Psoriatic Arthritis Treated with IL-17A or TNFα Inhibitors (IL-17Ai or TNFi)
Aisha Vadhariya¹, Sarah Ross¹, Brenna Brady², Helen Varker², Anh Thu Tran² and Jessica A Walsh³, ¹Eli Lilly and Company, Indianapolis, IN, ²Merative, Cambridge, MA, ³Salt Lake City Veterans Affairs Health and University of Utah Health, Division of Rheumatology, Salt Lake City, UT
Background/Purpose: The treatment paradigm for psoriatic arthritis (PsA) has changed over the last two decades, with increasing numbers of therapy options that target a variety…

« Previous Page
1
…
3
4
5
6
7
…
13
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].